Claudia Monari

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4802694/publications.pdf

Version: 2024-02-01

66	2,609	159585	206112
papers	citations	30 h-index	48 g-index

66	66	66	2021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Is recurrence possible in coronavirus disease 2019 (COVID-19)? Case series and systematic review of literature. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1-12.	2.9	45
2	Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues. Pharmaceutics, 2021, 13, 85.	4.5	1
3	SARS-CoV-2 Survival on Surfaces and the Effect of UV-C Light. Viruses, 2021, 13, 408.	3.3	77
4	Glucocorticoid-Induced Leucine Zipper-Mediated TLR2 Downregulation Accounts for Reduced Neutrophil Activity Following Acute DEX Treatment. Cells, 2021, 10, 2228.	4.1	6
5	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. Journal of Infection, 2021, 83, 467-472.	3.3	28
6	Optimized Extraction of Amikacin from Murine Whole Blood. Molecules, 2021, 26, 665.	3.8	0
7	Lactobacillus iners Cell-Free Supernatant Enhances Biofilm Formation and Hyphal/Pseudohyphal Growth by Candida albicans Vaginal Isolates. Microorganisms, 2021, 9, 2577.	3.6	13
8	Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm. Frontiers in Microbiology, 2020, 11, 2085.	3.5	12
9	In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood. Journal of Global Antimicrobial Resistance, 2020, 23, 4-8.	2.2	5
10	Anti-Biofilm Properties of Saccharomyces cerevisiae CNCM I-3856 and Lacticaseibacillus rhamnosus ATCC 53103 Probiotics against G. vaginalis. Microorganisms, 2020, 8, 1294.	3.6	15
11	Saccharomyces cerevisiae-Based Probiotics as Novel Antimicrobial Agents to Prevent and Treat Vaginal Infections. Frontiers in Microbiology, 2020, 11, 718.	3.5	35
12	Apoptosis of vaginal epithelial cells in clinical samples from women with diagnosed bacterial vaginosis. Scientific Reports, 2020, 10, 1978.	3.3	17
13	Vaginal Epithelial Cells Discriminate Between Yeast and Hyphae of Candida albicans in Women Who Are Colonized or Have Vaginal Candidiasis. Journal of Infectious Diseases, 2019, 220, 1645-1654.	4.0	30
14	Saccharomyces cerevisiae CNCM I-3856 as a New Therapeutic Agent Against Oropharyngeal Candidiasis. Frontiers in Microbiology, 2019, 10, 1469.	3.5	11
15	A Role for Yeast/Pseudohyphal Cells of Candida albicans in the Correlated Expression of NLRP3 Inflammasome Inducers in Women With Acute Vulvovaginal Candidiasis. Frontiers in Microbiology, 2019, 10, 2669.	3.5	14
16	Saccharomyces cerevisiaeâ€“based probiotic as novel anti-microbial agent for therapy of bacterial vaginosis. Virulence, 2018, 9, 954-966.	4.4	28
17	Carbapenemase-producing Enterobacteriaceae isolates resistant to last-line antibiotics in an Italian general hospital. New Microbiologica, 2018, 41, 274-281.	0.1	3
18	Autophagy and Reactive Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. albicans Morphotypes. Frontiers in Microbiology, 2016, 7, 879.	3.5	73

#	Article	IF	Citations
19	Carbapenem-Resistant Klebsiella pneumoniae: Results of a Laboratory Surveillance Program in an Italian General Hospital (August 2014â€“January 2015). Advances in Experimental Medicine and Biology, 2015, 901, 91-101.	1.6	7
20	Typing of Nosocomial Outbreaks of Acinetobacter baumannii by Use of Matrix-Assisted Laser Desorption Ionizationâ€“Time of Flight Mass Spectrometry. Journal of Clinical Microbiology, 2013, 51, 603-606.	3.9	68
21	Mouse Strain-Dependent Differences in Estrogen Sensitivity During Vaginal Candidiasis. Mycopathologia, 2013, 175, 1-11.	3.1	14
22	Elucidating the immunological function of theCryptococcus neoformanscapsule. Future Microbiology, 2013, 8, 1107-1116.	2.0	76
23	A Purified Capsular Polysaccharide Markedly Inhibits Inflammatory Response during Endotoxic Shock. Infection and Immunity, 2013, 81, 90-98.	2.2	37
24	Antibody Constant Region Peptides Can Display Immunomodulatory Activity through Activation of the Dectin-1 Signalling Pathway. PLoS ONE, 2012, 7, e43972.	2.5	17
25	Capsular Material of Cryptococcus neoformans: Virulence and Much More. Mycopathologia, 2012, 173, 375-386.	3.1	19
26	A critical role for FcgammaRIIB in up-regulation of Fas ligand induced by a microbial polysaccharide. Clinical and Experimental Immunology, 2011, 165, 190-201.	2.6	13
27	Microbial polysaccharide new insights for treating autoimmune diseases. Frontiers in Bioscience - Scholar, 2010, S2, 256-267.	2.1	5
28	A Microbial Polysaccharide Reduces the Severity of Rheumatoid Arthritis by Influencing Th17 Differentiation and Proinflammatory Cytokines Production. Journal of Immunology, 2009, 183, 191-200.	0.8	36
29	Capsular polysaccharide induction of apoptosis by intrinsic and extrinsic mechanisms. Cellular Microbiology, 2008, 10, 2129-2137.	2.1	37
30	Cytokine regulation of low-affinity IgE receptor (CD23) on monocytes from asthmatic subjects. Clinical and Experimental Immunology, 2008, 97, 248-253.	2.6	7
31	Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clinical and Experimental Immunology, 2008, 98, 217-223.	2.6	102
32	Indinavir-treatedCryptococcus neoformanspromotes an efficient antifungal immune response in immunosuppressed hosts. Medical Mycology, 2006, 44, 119-126.	0.7	14
33	Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cellular Microbiology, 2006, 8, 267-275.	2.1	68
34	Glucuronoxylomannan exhibits potent immunosuppressive properties. FEMS Yeast Research, 2006, 6, 537-542.	2.3	68
35	Microbial Immune Suppression Mediated by Direct Engagement of Inhibitory Fc Receptor. Journal of Immunology, 2006, 177, 6842-6851.	0.8	40
36	Influence of Indinavir on Virulence and Growth ofCryptococcus neoformans. Journal of Infectious Diseases, 2005, 191, 307-311.	4.0	40

#	Article	IF	Citations
37	Glucuronoxylomannan, a Microbial Compound, Regulates Expression of Costimulatory Molecules and Production of Cytokines in Macrophages. Journal of Infectious Diseases, 2005, 191, 127-137.	4.0	114
38	Cryptococcus neoformansCapsular Glucuronoxylomannan Induces Expression of Fas Ligand in Macrophages. Journal of Immunology, 2005, 174, 3461-3468.	0.8	88
39	Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. European Journal of Immunology, 2003, 33, 1041-1051.	2.9	45
40	Modulation of C5aR Expression on Human Neutrophils by Encapsulated and Acapsular Cryptococcus neoformans. Infection and Immunity, 2002, 70, 3363-3370.	2.2	41
41	Interleukinâ€12 Counterbalances the Deleterious Effect of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein gp120 on the Immune Response toCryptococcus neoformans. Journal of Infectious Diseases, 2001, 183, 51-58.	4.0	29
42	Interdependency of Interleukin-10 and Interleukin-12 in Regulation of T-Cell Differentiation and Effector Function of Monocytes in Response to Stimulation with Cryptococcus neoformans. Infection and Immunity, 2001, 69, 6064-6073.	2.2	68
43	Normalization of anti-cryptococcal activity and interleukin-12 production after highly active antiretroviral therapy. Aids, 2000, 14, 2699-2708.	2.2	14
44	T lymphocyte and monocyte interaction by CD40 / CD40 ligand facilitates a lymphoproliferative response and killing ofCryptococcus neoformans in vitro. European Journal of Immunology, 2000, 30, 1385-1393.	2.9	28
45	Dysregulation in IL-12 secretion by neutrophils from HIV-infected patients. Clinical and Experimental Immunology, 2000, 121, 311-319.	2.6	15
46	T lymphocyte and monocyte interaction by CD40â€‰/â€‰CD40 ligand facilitates a lymphoproliferative response and killing of Cryptococcus neoformans in vitro. European Journal of Immunology, 2000, 30, 1385-1393.	2.9	1
47	HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. Aids, 1999, 13, 2197-2207.	2.2	14
48	Neutrophils from Patients with Advanced Human Immunodeficiency Virus Infection Have Impaired Complement Receptor Function and Preserved FcÎ³ Receptor Function. Journal of Infectious Diseases, 1999, 180, 1542-1549.	4.0	43
49	B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology, 1999, 98, 27-35.	4.4	19
50	Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. Aids, 1999, 13, 653-660.	2.2	33
51	Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. European Journal of Immunology, 1998, 28, 114-121.	2.9	53
52	Cryptococcus neoformansandCandida albicansRegulate CD4 Expression on Human Monocytes. Journal of Infectious Diseases, 1998, 178, 1464-1471.	4.0	14
53	Human Immunodeficiency Virus Type 1 Envelope Protein gp120 Impairs Intracellular Antifungal Mechanisms in Human Monocytes. Journal of Infectious Diseases, 1998, 177, 347-354.	4.0	22
54	Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. European Journal of Immunology, 1998, 28, 114-121.	2.9	1

#	Article	IF	Citations
55	Involvement of C3a and C5a in Interleukin-8 Secretion by Human Polymorphonuclear Cells in Response to Capsular Material of Cryptococcus neoformans. Infection and Immunity, 1998, 66, 4324-4330.	2.2	4
56	Encapsulation of Cryptococcus neoformans with Glucuronoxylomannan Inhibits the Antigen-Presenting Capacity of Monocytes. Infection and Immunity, 1998, 66, 664-669.	2.2	81
57	Specific Antibody to Cryptococcus neoformans Alters Human Leukocyte Cytokine Synthesis and Promotes T-Cell Proliferation. Infection and Immunity, 1998, 66, 1244-1247.	2.2	37
58	Involvement of C3a and C5a in Interleukin-8 Secretion by Human Polymorphonuclear Cells in Response to Capsular Material ofCryptococcus neoformans. Infection and Immunity, 1998, 66, 4324-4330.	2.2	42
59	Monocyte dysfunction in patients with acquired immunodeficiency syndrome (AIDS) versus Cryptococcus neoformans. Journal of Infection, 1997, 35, 257-263.	3.3	17
60	Regulatory role of exogenous IL-10 in the development of immune response versus Cryptococcus neoformans. Clinical and Experimental Immunology, 1997, 109, 242-254.	2.6	30
61	Inhibition of fungicidal activity of polymorphonuclear leukocytes from HIV-infected patients by interleukin (IL)-4 and IL-10. Aids, 1996, 10, 477-483.	2.2	27
62	Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infection and Immunity, 1996, 64, 2846-2849.	2.2	169
63	Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infection and Immunity, 1996, 64, 2897-2903.	2.2	128
64	Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS. Journal of Infectious Diseases, 1995, 171, 1448-1454.	4.0	80
65	Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1 beta secretion from human monocytes. Infection and Immunity, 1995, 63, 2919-2923.	2.2	183
66	Role of human alveolar macrophages as antigen-presenting cells in Cryptococcus neoformans infection.. American Journal of Respiratory Cell and Molecular Biology, 1994, 11, 130-137.	2.9	88